Systemic Inflammation in Liver Cirrhosis (SILC)
Evaluation and Prognostic Indications of Systemic Inflammation in Liver Cirrhosis Patients
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Xing Wang, M.D.
- Phone Number: 86-20-85252156
- Email: md04wsh@mail2.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510630
- Department of Cardiology, the Third Affiliated Hospital, Sun Yat-sen University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Decompensated liver cirrhosis, with endoscopy-verified high-risk esophagogastric varices;
- Adult patients aged 18-75 years;
- Willing to anticipate and informed consent form obtained
Exclusion Criteria:
- History of prior radio-interventional therapy (TIPS or BRTO), liver transplantation, splenectomy, or hepatectomy;
- Non-sinusoidal cirrhosis (e.g. vascular cirrhosis);
- Coexistence with advanced hepatocellular carcinoma or other malignancies;
- Coexistence with severe systemic diseases and less than 3 months of expected survival time;
- Acute infection within 4 weeks before recruitment;
- Antibiotic use within 4 weeks before recruitment;
- Initial antiviral therapy for HBV or HCV within 4 weeks before recruitment;
- Pregnant or lactating women;
- Patients resistant to long-term follow-up
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
EGD+NSBB
Patients receiving both endoscopic therapy and non-selective beta-blockers for treating high-risk esophagogastric varices
|
|
EGD
Patients receiving mono endoscopic therapy for treating high-risk esophagogastric varices
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Upper Gastrointestinal Bleeding
Time Frame: One Year
|
Overt upper GI bleeding due to esophagogastric varices, ulcers and other causes; Identified by clinical manifestations, lab tests and endoscopy and measured by number/proportion of patients
|
One Year
|
|
Death
Time Frame: One Year
|
Deaths caused by variceal bleeding, hepatocellular carcinoma, liver failure, etc
|
One Year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
New or worsening acute decompensation event other than upper GI bleeding
Time Frame: One Year
|
Ascites, Hepatic encephalopathy, systemic infection, spontaneous bacterial peritonitis, hepatorenal syndrome, etc Identified by clinical manifestations, lab tests and images according to renown practice guidelines and measured by number/proportion of patients
|
One Year
|
|
Liver transplantation/ Transfer to other non-endoscopic therapies
Time Frame: One Year
|
Undergo liver transplantation, or transferred to surgical, radio-interventional, or other non-endoscopic therapies; Measured by number/proportion of patients
|
One Year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Bin Wu, Ph.D, Department of Gastroenterology, Third Affiliated Hospital of Sun Yar-sen University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SILC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.